Raw Material Nsi-189 Nootropics Base Nsi-189 Powder Phosphate Nsi-189

• Powder: Yes
• Customized: Customized
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Model NO.: Dsung-Nsi 189
• Product Name: Nsi-189
• CAS: 1270138-40-3
• Einecs: 1592732-453-0
• Color: off-Whtie
• Grade: Pharmaceutical Grade
• Detection Method: HPLC UV etc.
• Shelf Life: 2 Year
• Storage Temp: -20c
• Molecular Weight: 366.4998
• Density: 1.128-1.140 /Cm3(Predicted)
• Boiling Point: 479.7c-584.7c(Predicted)
• Solubility DMSO: 27mg/Ml (73.67mm; Need Ultrasonic and Warmin)
• Acidity Coefficient: 6.08-6.28(Predicted)
• Packing: Pack in Bag or Drums
• Storage: Store in a Well-Closed Container Away From
• Transport Package: Negotiable
• Specification: HPLC99%
• Trademark: D-Sung
• Origin: Shaanxi
• Production Capacity: 300kg

Product Description

Raw Material Nsi-189 Nootropics Base Nsi-189 Powder Phosphate Nsi-189

Product Description

 

Product Details

 

Product Name	NSI-189
Color	Off-White
Packing	Pack in bag or drums
Storage conditions	-20°C
Shelf Life	2 Year

    NSI-189 is a small molecule drug with clinical treatment for major depressive disorders and preclinical treatment for Angel-man syndrome, radiation-induced cognitive impairment, type 1 and type 2 diabetes, and stroke.

Application & Function

 

    NSI-189 is a benzylpiperizine-aminiopyridine, a novel chemical entity that stimulates neurogenesis of human hippocampus-derived neural stem cells in vitro and stimulates neurogenesis in murine hippocampus in vivo.  Emerging evidence also indicates that NSI-189 phosphate has regionally specific effects insofar as neurogenesis is observed largely in the subventricular zone of the hippocampus.  Results from a preliminary proof of concept study suggests that NSI-189 may be capable of mitigating depressive symptoms and improve cognitive function in adults with DSM-5-defined Major Depressive Disorder (MDD).
   
    NSI-189 is a new investigational antidepressant, which is purported to work differently from existing antidepressants.  Researchers suggest this drug may potentially help those who do not respond to conventional medications.  Research is also ongoing for its cognitive-enhancing effects.  However, NSI-189 failed in a recent clinical trial.  Learn about all the research behind this drug.

    1.Cognitive impairment and radiation-induced cognitive impairments
    2.Diabetic neuropathy, a form of nerve damage caused by diabetes
    3.Ischemic stroke
    4.Angelman Syndrome (a genetic disorder that causes developmental disabilities and nerve-related symptoms)

Specification